Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
- PMID: 10440017
- DOI: 10.1176/jnp.11.3.392
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
Abstract
Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine. Eight subjects had dementia. Six subjects (29%) discontinued treatment prematurely because of drowsiness. Delusions and hallucinations improved significantly, and 80% were rated as much or very much improved. There was no worsening of parkinsonism or cognition.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
